Testicular cancer is the success story of oncology. Even patients presenting with widely metastatic disease can be cured — the overall 5-year survival rate exceeds 95%, the highest of any solid tumor. This is largely because germ cell tumors are exquisitely sensitive to cisplatin-based chemotherapy.
Testicular cancer arises from the germ cells of the testis — the cells normally responsible for producing sperm. Approximately 95% of testicular tumors are germ cell tumors (GCTs), which are further divided into seminomas and non-seminomatous germ cell tumors (NSGCTs). The remaining 5% are stromal tumors (Leydig cell, Sertoli cell) and lymphomas of the testis.
The average age at diagnosis is 33, and the disease is most common in men between ages 15 and 35 — making it unique among cancers in primarily affecting young, otherwise healthy men. Despite this, most patients are cured and return to full health, work, and family life.
New U.S. cases/year
Average age at diagnosis
Deaths/year (very low given incidence)
Overall 5-year survival
The distinction between seminoma and non-seminoma is the most clinically important classification in testicular cancer — it directly determines treatment approach, chemotherapy sensitivity, and surveillance protocols.
Seminomas arise from germ cells that retain a more primitive, undifferentiated appearance. They tend to grow more slowly, spread later, and are highly radiosensitive — a property that shapes their treatment.
AFP is never elevated by pure seminoma. If AFP is elevated, the tumor must contain non-seminomatous elements and should be treated as a non-seminoma regardless of histology.
Most common; uniform sheets of large cells with clear cytoplasm. Peak incidence age 30–40.
Rare; occurs in older men (50+); very low metastatic potential; excellent prognosis with orchiectomy alone.
NSGCTs contain one or more of four distinct cell types and tend to grow faster and spread earlier than seminomas. They are equally curable with platinum-based chemotherapy but require different treatment algorithms.
Mixed GCTs — tumors containing both seminomatous and non-seminomatous elements — are treated as non-seminomas.
Most common NSGCT component; high-grade, aggressive; frequently associated with vascular invasion. Raises hCG.
Produces AFP; most common testicular tumor in children; aggressive in adults.
Rarest and most aggressive NSGCT; markedly elevated hCG; hematogenous spread (lungs, brain) even at small primary tumor size.
Contains mature or immature tissue from multiple germ layers. May appear benign but can harbor malignant transformation and is chemotherapy-resistant — surgical resection is the only cure for teratoma.
About 40–50% of all testicular GCTs contain more than one cell type. The treatment strategy is always based on the most aggressive element present — a tumor with any non-seminomatous component is managed as a non-seminoma.
Most men who develop testicular cancer have no identifiable risk factor. When risk factors are present, they often relate to abnormal testicular development or genetic predisposition.
The strongest single risk factor — increases testicular cancer risk 3–5-fold, even after orchiopexy. Intra-abdominal undescended testes carry higher risk than inguinal ones. Risk persists even after surgical correction, though orchiopexy before puberty reduces but does not eliminate the elevated risk.
A prior history of testicular cancer in the contralateral testis carries an approximately 2–5% risk of a second primary tumor. A father with testicular cancer confers a 4–6-fold increased risk; a brother with the disease increases risk 8–10-fold.
White men have a 4–5-fold higher incidence of testicular GCTs than Black or Asian men in the United States. The reason is not well understood but is likely multifactorial (genetic, environmental, developmental).
Isochromosome 12p (i12p) — a specific chromosomal abnormality — is present in virtually all GCTs and is pathognomonic of the disease. Germline mutations in BRCA2 and mismatch repair genes are associated with increased testicular GCT risk in a small proportion of patients.
Previously called carcinoma in situ (CIS) of the testis, GCNIS is the precursor lesion of all GCTs except spermatocytic seminoma. It is found in ~5% of contralateral testes in men with unilateral GCT and is associated with atrophic testes, cryptorchidism, and infertility.
A cluster of conditions — cryptorchidism, hypospadias, poor semen quality, and testicular GCT — are thought to share a common developmental origin related to in utero exposure to endocrine-disrupting chemicals or abnormal gonadal development.
Testicular cancer most often presents as a painless abnormality discovered on self-examination or incidentally. The classic triad — painless testicular mass, heaviness, and dull ache — is well recognized but not universal. Pain is actually present in about 20% of cases and should not be used to rule out cancer.
A new hardness, nodule, or lump within the body of the testicle — distinct from the softer epididymis behind. The most common presenting finding.
A sensation of weight or fullness in the scrotum, or visible swelling of one side. May be mistaken for hydrocele or epididymo-orchitis.
A persistent, low-grade discomfort on one side. Often attributed to muscle strain or injury, causing delayed diagnosis.
A new accumulation of fluid around the testicle — especially without prior injury or infection — warrants ultrasound to exclude an underlying tumor.
Breast tenderness or enlargement in a young man — caused by hCG secretion from choriocarcinoma or embryonal carcinoma components — can be the first noticed symptom.
Back or flank pain (retroperitoneal nodes), cough or hemoptysis (pulmonary metastases), headache or neurological symptoms (brain metastases — more common with choriocarcinoma).
Testicular cancer is frequently misdiagnosed initially as epididymo-orchitis or scrotal trauma. If symptoms do not resolve completely with antibiotics or within 2–4 weeks, scrotal ultrasound is mandatory. Delays in diagnosis are common and can allow stage progression.
The diagnostic workup for a suspected testicular mass is urgent — scrotal ultrasound is performed the same day or within 24–48 hours in most guidelines. Once confirmed, radical inguinal orchiectomy is both diagnostic and therapeutic. Transscrotal biopsy is absolutely contraindicated — it disrupts lymphatic drainage and changes the pattern of lymph node spread.
High-frequency ultrasound (7.5–15 MHz) of both testes is the first-line imaging study. It can distinguish intratesticular from extratesticular lesions, characterize the mass (solid, cystic, mixed), assess vascularity, and examine the contralateral testis. Sensitivity for testicular cancer approaches 100%. Results are typically available immediately.
AFP (alpha-fetoprotein), hCG (human chorionic gonadotropin), and LDH (lactate dehydrogenase) must be measured before orchiectomy — their pre-operative levels are incorporated into staging. Elevated AFP always indicates non-seminomatous elements regardless of histology. Markers should be repeated post-operatively to assess half-life decline and detect residual disease.
The testicle is removed through a groin (inguinal) incision — never a scrotal incision. This preserves the lymphatic drainage pathway to the retroperitoneal nodes and avoids seeding inguinal lymph nodes. The spermatic cord is ligated at the internal inguinal ring before the testicle is delivered. The specimen provides definitive histological diagnosis and pathological T staging.
Contrast-enhanced CT is the staging workhorse — it identifies retroperitoneal lymph node metastases (the primary drainage site), assesses the size of any nodes (nodes >10 mm in short axis are considered pathological), and detects pulmonary and visceral metastases. Performed after orchiectomy to allow post-operative healing.
Brain MRI: recommended for patients with high-volume metastatic disease, markedly elevated hCG, or any neurological symptoms — choriocarcinoma spreads hematogenously to the brain. PET-CT: used in seminoma to assess residual retroperitoneal masses after chemotherapy (PET avidity in residual mass post-chemo suggests viable tumor requiring resection or further treatment).
Tumor markers are central to testicular cancer management in a way unique among solid tumors — they guide staging, assess treatment response, and detect early recurrence. Understanding what each marker means is essential for patients navigating their care.
Normal
<10 ng/mL
Half-life
5–7 days
Produced by
Yolk sac tumor; hepatocellular carcinoma (non-GCT)
In seminoma
NEVER elevated by pure seminoma
If AFP is elevated in a patient with biopsy-proven seminoma, assume occult non-seminomatous elements are present and treat as NSGCT. AFP should normalize after orchiectomy if no metastatic disease remains — failure to decline per its half-life suggests residual tumor.
Normal
<1 mIU/mL
Half-life
24–36 hours
Produced by
Syncytiotrophoblasts; choriocarcinoma highest levels
In seminoma
Mildly elevated in ~10–15% of pure seminomas
Markedly elevated hCG (thousands to millions of mIU/mL) strongly suggests choriocarcinomatous elements and is associated with early hematogenous spread including to the brain. Can cause gynecomastia. hCG should normalize within days after successful treatment given its short half-life.
Normal
Varies by lab (~100–220 U/L)
Half-life
Variable; non-specific
Produced by
Any rapidly dividing tissue; correlates with tumor bulk
Specificity
Low — elevated in many conditions
LDH is an indirect marker of tumor burden and metabolic activity. It is incorporated into the IGCCCG risk classification for metastatic disease and is an independent prognostic factor. Marked elevation in seminoma may be the only marker abnormality and correlates with disease extent.
Approximately 20% of NSGCTs and virtually all seminomas are marker-negative at baseline. Absence of marker elevation does not exclude cancer — it simply means recurrence cannot be detected by markers alone, making imaging surveillance more critical.
After orchiectomy, markers should decline according to their known half-lives. AFP should halve every 5–7 days; hCG should halve every 24–36 hours. Slower-than-expected decline — even if still within normal range — implies residual disease and should trigger staging workup.
Testicular cancer is staged using the AJCC TNM system with an important addition: the S (serum tumor marker) category. Post-orchiectomy marker levels are formally incorporated into staging — unique among solid tumors.
No evidence of lymph node or distant metastatic spread after orchiectomy and staging CT. Markers must normalize post-orchiectomy to confirm Stage I. Stage IS (marker-positive Stage I) indicates subclinical metastatic disease and is treated as metastatic. Approximately 75–80% of seminomas and 50–60% of NSGCTs present at Stage I.
Metastasis in regional lymph nodes, all ≤2 cm in maximum dimension. Markers normal or mildly elevated (S1). Cure rates remain very high — exceeding 95% for seminoma and 90%+ for NSGCT with appropriate treatment.
Retroperitoneal lymph node metastases 2–5 cm in size, or multiple nodes <5 cm. Chemotherapy or radiation (for seminoma) is typically preferred over primary RPLND in this setting.
ny retroperitoneal lymph node >5 cm. Chemotherapy is the standard treatment for both seminoma and NSGCT. Post-chemotherapy RPLND may be needed for residual masses in NSGCT.
Spread beyond the retroperitoneum: pulmonary (most common), visceral (liver, bone, brain), or non-regional lymph nodes. Also includes stage IS (persistently elevated markers after orchiectomy). Treated with cisplatin-based combination chemotherapy — cure is achievable even at Stage III in the majority of patients.
| pT Stage | Description | Significance |
|---|---|---|
| pT1 | Confined to testis and epididymis; no vascular/lymphatic invasion; rete testis invasion allowed in seminoma only if invasion is limited | Lower metastatic risk; favorable for surveillance in seminoma (Stage I) |
| pT1a / pT1b | NSGCT only: pT1a = <3 cm; pT1b = ≥3 cm. Both confined to testis without LVI | Tumor size ≥3 cm in seminoma is an independent risk factor for relapse on surveillance |
| pT2 | Lymphovascular invasion (LVI) present, OR invasion of rete testis (for NSGCT), OR invasion of hilar soft tissue or epididymis | LVI is the strongest predictor of occult retroperitoneal metastases in Stage I NSGCT — used to guide adjuvant treatment vs. surveillance decisions |
| pT3 | Invasion of spermatic cord | Indicates more advanced local disease; higher risk of relapse |
| pT4 | Invasion of scrotum | Rare; changes lymphatic drainage pattern — inguinal nodes now at risk |
For patients with metastatic disease (Stage II–III), the International Germ Cell Cancer Collaborative Group (IGCCCG) classification defines three prognostic groups based on histology, primary site, metastatic sites, and tumor marker levels. This classification directly determines the intensity of first-line chemotherapy.
| Risk Group | Histology | Criteria | 5-Year Survival |
|---|---|---|---|
| Good Risk | Seminoma | Any primary site; no non-pulmonary visceral metastases; any LDH, any hCG | ~92% |
| Good Risk | NSGCT | Testis/retroperitoneal primary; no non-pulmonary visceral metastases; AFP <1,000, hCG <5,000, LDH <1.5× ULN | ~92% |
| Intermediate Risk | Seminoma | Any primary site; non-pulmonary visceral metastases (liver, bone, brain); any markers | ~72% |
| Intermediate Risk | NSGCT | Testis/retroperitoneal primary; no non-pulmonary visceral metastases; AFP 1,000–10,000 OR hCG 5,000–50,000 OR LDH 1.5–10× ULN | ~72% |
| Poor Risk | Seminoma | No poor-risk seminoma category exists (all seminoma is good or intermediate) | N/A |
| Poor Risk | NSGCT | Mediastinal primary, OR non-pulmonary visceral metastases, OR AFP >10,000, OR hCG >50,000, OR LDH >10× ULN | ~48% |
Contemporary survival rates are somewhat higher than the original 1997 publication — good-risk survival now approaches 96%, intermediate-risk ~89%, and poor-risk ~67%, reflecting improvements in supportive care and treatment delivery over the past three decades.
All testicular cancer treatment begins with radical inguinal orchiectomy. What follows depends on histology (seminoma vs. non-seminoma), pathological T stage, tumor markers, and CT findings. The goal at every stage is cure — testicular cancer is managed aggressively even at Stage III because cure is achievable.
The primary and universal first treatment for any testicular cancer — performed through an inguinal (groin) incision with high ligation of the spermatic cord at the internal ring. The procedure is typically performed under general anesthesia and takes 30–45 minutes. Most men go home the same day and return to normal activity within 1–2 weeks.
The entire testis and spermatic cord are removed as a single specimen. Recovery involves 1–2 weeks of limited activity and scrotal support. Most men have no significant change in testosterone levels or sexual function after removal of one testis, as the remaining testis compensates. Testosterone levels should be checked post-operatively and supplemented if low.
A saline-filled silicone testicular prosthesis can be implanted at the time of orchiectomy or as a delayed procedure. Prosthesis placement is a personal choice — it restores scrotal appearance but has no functional role. Dr. Bansal discusses this option with all patients undergoing orchiectomy.
In rare, carefully selected cases — a small lesion (<2 cm) in a solitary testis or bilateral synchronous tumors — testis-sparing excision of the tumor with frozen section margin confirmation may be appropriate to preserve hormonal function. This is only performed at experienced centers and requires strict surveillance afterward.
Following orchiectomy for Stage I seminoma, three management options are available. The preferred approach is active surveillance for most men — surveillance avoids radiation and chemotherapy in the ~80% of Stage I patients who are already cured by orchiectomy.
Preferred for most Stage I
CT and marker monitoring per protocol (frequent in year 1, tapering to annually by year 5). Relapse rate is ~15–20%; virtually all relapses are detected early and successfully salvaged with radiation or chemotherapy.
Risk factors for relapse: tumor >4 cm, rete testis invasion. High-risk patients may prefer adjuvant treatment.
Adjuvant — reduces relapse to ~3–5%
A single cycle of carboplatin (AUC 7) reduces the relapse rate from ~20% to ~3–5%. Preferred adjuvant option over radiation — equivalent cancer control without the long-term risk of secondary malignancies from pelvic/para-aortic radiation.
One short outpatient infusion; mild, temporary side effects. Does not affect fertility long-term.
Alternative — now less preferred
20 Gy to the para-aortic lymph nodes. Very effective at preventing relapse (~3%) but exposes bowel, left kidney, and scatter radiation to contralateral testis. Associated with small but real increase in secondary gastrointestinal malignancies decades later.
Now generally reserved for patients who cannot receive carboplatin.
Radiation therapy to the para-aortic and ipsilateral pelvic (dog-leg) field remains standard for Stage IIA (nodes ≤2 cm), achieving >95% cure. For Stage IIB (nodes 2–5 cm), both radiation and BEP×3 chemotherapy are accepted — chemotherapy is increasingly preferred for IIB given lower relapse rates. Stage IIC (nodes >5 cm): BEP chemotherapy is standard.
BEP (bleomycin, etoposide, cisplatin) chemotherapy — 3 cycles for good-risk, 4 cycles for intermediate-risk. Residual retroperitoneal masses post-chemotherapy in seminoma are common and mostly necrotic/fibrotic. PET-CT at 6–8 weeks after completing chemotherapy guides whether resection is needed: PET-negative residual masses are observed; PET-positive masses with diameter >3 cm warrant further evaluation or resection.
Lymphovascular invasion (LVI) on pathology is the most important risk factor for relapse — present in ~50% of Stage I NSGCTs and associated with a 40–50% risk of retroperitoneal relapse without additional treatment. Management is stratified accordingly.
~15–20% relapse risk
Active surveillance is the preferred approach — most relapses occur in the retroperitoneum and are detected on surveillance CT, then cured with BEP chemotherapy.
Alternatively, 1 cycle of BEP chemotherapy reduces relapse to <3%. RPLND is less commonly chosen for Stage I in current guidelines but is an option at experienced centers.
~40–50% relapse risk without adjuvant treatment
Adjuvant BEP ×1 cycle is recommended — reduces relapse risk to <3% and is the preferred approach for men with LVI who prefer to minimize relapse risk over surveillance burden.
Active surveillance remains acceptable for men who clearly understand and commit to the surveillance protocol; RPLND is another option.
Primary RPLND is an option for selected patients at experienced centers. BEP ×3 cycles is equally effective and is preferred when markers are elevated. Stage IIB/IIC: BEP ×3–4 cycles is standard. Post-chemotherapy RPLND is performed for any residual retroperitoneal mass >1 cm — teratoma and residual viable tumor cannot be distinguished from fibrosis by imaging alone.
BEP ×3 cycles for good-risk; BEP ×4 cycles for intermediate- and poor-risk disease. Bleomycin dose modification or substitution with etoposide (EP ×4) is used in patients with pulmonary comorbidities. Post-chemotherapy RPLND is standard for any residual retroperitoneal mass — even small ones — given the risk of teratoma and viable tumor.
RPLND is a surgical procedure that removes the lymph nodes in the retroperitoneum (the primary landing zone for testicular cancer spread) through an abdominal incision or, increasingly, a minimally invasive (robotic or laparoscopic) approach. It is both a staging and therapeutic procedure unique to testicular cancer management.
Stage I–IIA NSGCT
Performed as the definitive treatment for clinical Stage I or IIA NSGCT in lieu of surveillance or chemotherapy. Provides precise pathological staging of lymph nodes and is curative for the majority of patients with limited nodal disease.
Patients with pN1 (1–5 positive nodes, all <2 cm, no extranodal extension) have a low enough relapse risk that observation alone post-RPLND is acceptable.
After BEP for Stage II–III NSGCT
Standard of care for any residual retroperitoneal mass ≥1 cm after chemotherapy in NSGCT. Pathological findings: necrosis/fibrosis (~45%), teratoma (~40%), viable GCT (~15%). Even small residual masses may harbor teratoma — which can grow (“growing teratoma syndrome”) and cannot be treated with chemotherapy.
Preserving ejaculatory function
Standard RPLND can damage the sympathetic nerve fibers that control antegrade ejaculation, resulting in retrograde ejaculation (dry orgasm) in up to 50–90% of patients. Nerve-sparing (template) RPLND, when oncologically appropriate, preserves these nerves and maintains antegrade ejaculation in 80–90% of patients.
Robotic RPLND (available at select centers including Bansal Urology) offers improved visualization of nerve structures and may further reduce ejaculatory dysfunction.
Platinum-based chemotherapy is the systemic backbone of testicular cancer treatment. BEP (bleomycin, etoposide, cisplatin) is the most widely used regimen in the world and has demonstrated consistent cure rates across all stages of metastatic GCT since the 1980s.
| Regimen | Drugs | Setting | Cycles | Notes |
|---|---|---|---|---|
| BEP | Bleomycin, Etoposide, Cisplatin | First-line metastatic; adjuvant Stage I high-risk; Stage IIB–III | 3 (good-risk) or 4 (intermediate/poor-risk) | Gold standard for over 40 years; each cycle is 21 days; cisplatin is the active backbone |
| EP | Etoposide, Cisplatin | Good-risk metastatic disease when bleomycin is contraindicated | 4 cycles | Used when pulmonary bleomycin toxicity risk is high (prior lung disease, older age, heavy smoking, impaired renal function) |
| Carboplatin ×1 | Carboplatin (AUC 7) | Adjuvant Stage I seminoma | 1 cycle | Single outpatient infusion; reduces Stage I seminoma relapse to ~3–5%; does not impair fertility long-term |
| BEP ×1 | Bleomycin, Etoposide, Cisplatin | Adjuvant Stage I NSGCT (LVI present) | 1 cycle | Reduces relapse risk from ~40–50% to <3% in LVI-positive Stage I NSGCT |
| VeIP / TIP | Vinblastine/Ifosfamide/Cisplatin or Taxol/Ifosfamide/Cisplatin | Second-line (salvage) after BEP failure | 4 cycles | Standard salvage regimens; TIP increasingly preferred over VeIP in many centers |
| High-dose chemotherapy (HDCT) + ASCT | Carboplatin + Etoposide (CE) × 2–3 cycles | Second-line or beyond for refractory/relapsed GCT | 2–3 cycles | Autologous stem cell transplant with high-dose carboplatin/etoposide; curative in 25–50% of patients who fail conventional salvage chemotherapy |
Bleomycin can cause interstitial lung injury. Risk factors include cumulative dose, smoking, renal impairment, and supplemental oxygen. Pulmonary function tests are monitored during treatment. In patients with significant pulmonary risk, bleomycin is omitted (EP ×4 substituted).
Cisplatin causes permanent changes in hearing (high-frequency hearing loss), neurotoxicity (peripheral neuropathy), and nephrotoxicity. Aggressive hydration and hearing monitoring are used during treatment. Long-term ototoxicity monitoring is part of survivorship care.
Although most patients with testicular GCT are cured with first-line treatment, approximately 20–30% of patients with metastatic disease will relapse. The majority of relapses can still be cured — testicular cancer retains sensitivity to second-line therapy to a degree rare among solid tumors.
TIP (paclitaxel, ifosfamide, cisplatin) or VeIP (vinblastine, ifosfamide, cisplatin) for 4 cycles. Complete response rates of 25–40% in platinum-sensitive relapse; lower in platinum-refractory disease.
The preferred salvage approach at major centers, particularly for patients relapsing after one prior line of platinum-based therapy or those with poor-risk relapse features. Two to three cycles of high-dose carboplatin + etoposide with autologous stem cell support. Cure rates of 25–60% depending on prior therapy and relapse risk factors. Indiana University and Memorial Sloan Kettering have published extensive experience with this approach.
Late relapses (>2 years after initial chemotherapy) often contain teratoma or viable GCT and are frequently managed surgically given lower chemotherapy sensitivity. Resection of isolated late-relapse lesions — in retroperitoneum, lung, mediastinum, or brain — can achieve long-term cure in a subset of patients.
Pembrolizumab has shown modest activity in refractory GCT in small studies. Targeted agents (cabazitaxel, gemcitabine + oxaliplatin) have activity in heavily pretreated patients. Enrollment in clinical trials should be strongly encouraged for patients with multiply-relapsed disease.
Even before any chemotherapy or radiation is administered, baseline fertility may be impaired in men with testicular cancer — likely due to the same gonadal dysfunction that contributes to cancer development. After chemotherapy, fertility can recover — but this is not guaranteed. Banking sperm before any treatment preserves options.
Testicular cancer and its treatment can affect fertility through multiple mechanisms. Understanding these helps young men make informed decisions about family planning before and after treatment.
Impact: low if contralateral testis is normal
Removal of one testicle reduces sperm production by approximately 50%, but most men with a normal contralateral testis maintain adequate fertility. Testosterone production is generally maintained by the remaining testis.
If the remaining testis is atrophic (small) or shows signs of GCNIS, fertility may be significantly impaired — sperm banking is especially important in these cases.
Impact: temporary azoospermia; long-term recovery common
Cisplatin and etoposide damage spermatogonia, causing temporary azoospermia (no sperm) during and for several months after treatment. Sperm counts typically begin recovering at 12–18 months; most men recover adequate sperm production within 2–5 years.
The risk of permanent infertility increases with the number of chemotherapy cycles and cumulative cisplatin dose. 1–2 cycles carry very low permanent infertility risk; 4+ cycles carry higher risk.
Impact: scatter dose to contralateral testis
Even with shielding, scatter radiation to the contralateral testis can cause temporary azoospermia. Full recovery typically occurs within 12–24 months after completing radiation. The risk of permanent damage depends on the total scattered dose.
Modern, more targeted radiation fields (para-aortic only, omitting pelvic field) reduce scattered dose and improve fertility preservation.
Impact: ejaculatory dysfunction (not sperm production)
Non-nerve-sparing RPLND damages sympathetic nerves controlling ejaculation, causing retrograde ejaculation (orgasm without emission of semen). Sperm production and testosterone are unaffected — fertility can be preserved through electroejaculation or sperm retrieval followed by assisted reproduction.
Nerve-sparing RPLND preserves antegrade ejaculation in 80–90% of patients.
Semen samples can be collected and cryopreserved at a fertility clinic within 24–48 hours. Most men can produce an adequate sample by masturbation. Even men with very low sperm counts may be able to bank sperm for use with intracytoplasmic sperm injection (ICSI). Cost ranges from $500–1,000 for initial banking plus annual storage fees; some insurance plans cover this for cancer patients.
After chemotherapy, most guidelines recommend waiting 12–24 months before attempting pregnancy, allowing full sperm DNA integrity recovery. Chromosomal abnormalities in sperm are more common in the first 12 months after chemotherapy completion.
The testis that does not contain the index cancer requires careful attention — it is at elevated risk for both a second GCT and for germ cell neoplasia in situ (GCNIS), the precursor lesion.
Approximately 2–5% of men with unilateral testicular GCT will develop a metachronous (subsequent) tumor in the contralateral testis during their lifetime. The risk is highest in men with a small or atrophic contralateral testis and those with a history of cryptorchidism. Regular scrotal self-examination and annual ultrasound surveillance of the contralateral testis are therefore recommended.
Routine biopsy of the contralateral testis to detect GCNIS is performed at some European centers, particularly in men with an atrophic contralateral testis (<12 mL volume) or cryptorchidism history. If GCNIS is identified, low-dose radiation (18–20 Gy) to the contralateral testis eliminates the GCNIS and prevents progression — at the cost of infertility from that testis. This is balanced against the low overall prevalence of GCNIS in the general GCT population (~5%) and the treatability of metachronous GCTs if they do develop. Contralateral testis biopsy is not routine practice in the United States but may be discussed in high-risk patients.
Men who lose both testes (from bilateral GCTs or bilateral orchiectomy) require lifelong testosterone replacement therapy. Levels should be monitored and maintained within the normal range to preserve energy, sexual function, bone density, and overall health.
Because testicular cancer affects primarily young men who are often cured, the long-term consequences of treatment are critically important — survivors may live 40–50 years after completing therapy. Survivorship care should begin at the end of active treatment and continue long-term.
| Late Effect | Relevant Treatment(s) | Time Course | Management / Monitoring |
|---|---|---|---|
| Peripheral neuropathy | Cisplatin | May be permanent; often partial recovery over years | Neurological assessment; duloxetine for symptomatic neuropathy; physical therapy |
| Hearing loss (ototoxicity) | Cisplatin | Permanent; high-frequency loss most common | Audiological evaluation at baseline, during, and after treatment; hearing aids if significant |
| Pulmonary fibrosis | Bleomycin | May progress; risk higher with higher cumulative doses | Pulmonary function tests during and after treatment; avoid high inspired oxygen concentrations during any surgery |
| Cardiovascular disease | Cisplatin, radiation (if cardiac field irradiated) | Elevated risk begins years after treatment; persists long-term | Cardiovascular risk factor management (blood pressure, lipids, smoking, exercise); cisplatin associated with hypertension and endothelial dysfunction |
| Secondary malignancies | Etoposide (AML risk); radiation (solid tumor risk) | Years to decades later | Etoposide-related leukemia risk is dose-dependent; avoid cumulative doses >2,000 mg/m². Radiation-related secondary cancers in the radiation field — another reason to prefer chemotherapy over radiation for Stage I |
| Metabolic syndrome | Cisplatin, gonadal hormone changes | Months to years | Weight, blood pressure, lipid, and glucose monitoring; lifestyle counseling; testosterone replacement if hypogonadal |
| Hypogonadism | Chemotherapy, radiation to contralateral testis, bilateral orchiectomy | May develop after treatment completion | Annual testosterone monitoring; testosterone replacement therapy if symptomatic hypogonadism develops |
| Retroperitoneal fibrosis / bowel adhesions | RPLND, radiation | Months to years post-treatment | May cause bowel obstruction or ureteral obstruction requiring intervention; monitored with imaging during follow-up |
Men who received bleomycin-containing chemotherapy should always inform their anesthesiologist before any future surgical procedure. High inspired oxygen concentrations (FiO₂ >0.25) during general anesthesia can trigger severe, potentially fatal pulmonary toxicity (bleomycin-oxygen toxicity) months to years after treatment. This is a lifelong consideration.
Testicular cancer has the best prognosis of any metastatic solid tumor. Even at Stage III, the majority of patients are cured with current treatments. The IGCCCG risk classification is the primary prognostic tool for metastatic disease.
| Stage / Risk Group | 5-Year Disease-Specific Survival | Notes |
|---|---|---|
| Stage I (all histologies) | >99% | Virtually all patients cured; surveillance saves most men from unnecessary treatment |
| Stage IIA–IIB | ~95–98% | Excellent outcomes with radiation (seminoma) or chemotherapy/RPLND (NSGCT) |
| Stage IIC (bulky nodes) | ~90–93% | Chemotherapy highly effective; post-chemo RPLND may be required in NSGCT |
| Stage III — Good risk (IGCCCG) | ~92–96% | BEP ×3; majority cured with first-line therapy |
| Stage III — Intermediate risk | ~72–89% | BEP ×4; higher relapse rate but salvage therapy effective |
| Stage III — Poor risk (NSGCT) | ~48–67% | BEP ×4; salvage HDCT + ASCT can cure a significant proportion of relapsers |
Survival rates in the right column reflect contemporary data (updated 2022 IGCCCG analysis), which show improved outcomes over the original 1997 publication due to better supportive care, antiemetics, and treatment delivery at specialized centers.
Outcomes for metastatic testicular cancer are significantly better at high-volume centers with experience in RPLND, high-dose chemotherapy, and GCT management. If you have metastatic disease or require complex post-chemotherapy surgery, referral to a GCT center of excellence is appropriate.
Surveillance after treatment for testicular cancer is intensive in the first 2 years — when the vast majority of relapses occur — and tapers significantly over time. Because relapses are almost always curable when detected early, consistent follow-up is as important as the initial treatment.
| Stage & Treatment | Year 1 | Year 2 | Years 3–5 | Beyond Year 5 |
|---|---|---|---|---|
| Stage I Seminoma (surveillance) | CT every 3–4 months; markers + exam every 3 months | CT every 6 months; markers + exam every 3–6 months | CT annually; annual exam + markers | Annual exam; CT every 2 years to year 10 |
| Stage I Seminoma (adjuvant carboplatin or RT) | CT at 3–4 and 12 months; markers every 3 months | CT at 24 months; markers every 6 months | Annual CT + markers | Annual exam; CT every 2 years |
| Stage I NSGCT (surveillance) | CT every 2–3 months; markers + exam monthly | CT every 3–4 months; markers + exam every 2 months | CT every 6 months; markers annually | Annual exam ± markers; CT as clinically indicated |
| Stage I NSGCT (BEP ×1 or RPLND) | CT at 3 and 12 months; markers every 3 months | CT at 24 months; markers every 3–6 months | Annual markers + exam; CT as indicated | Annual exam |
| Stage II–III (all histologies, after chemotherapy) | CT every 2–3 months; markers monthly | CT every 3–4 months; markers every 2 months | CT every 6 months; markers every 3–6 months | Annual imaging; annual markers and exam |
Testicular GCT can rarely relapse many years or even decades after apparent cure — particularly NSGCTs containing teratoma. Any new retroperitoneal or pulmonary mass, even years after treatment, should be evaluated promptly with markers and imaging. Late relapses are often treated surgically.
Annual serum testosterone measurement is recommended in all survivors — hypogonadism can develop gradually and may be subclinical for years before causing symptoms. Early identification and treatment improves quality of life and long-term metabolic health.
Monthly self-examination is the most reliable way for a man to detect testicular cancer early — before it spreads. It takes less than one minute and requires no equipment.
After a warm bath or shower, when the scrotal skin is relaxed. Perform monthly — the same day each month helps build a routine.
Hold the testicle between the thumbs and fingers of both hands and gently roll it. The testicle should feel smooth, firm, and egg-shaped. The epididymis — a soft, rope-like structure at the back — is normal and should not be confused with a lump.
Any new hard lump, nodule, or firm area within the testis itself. Any change in size, shape, or consistency. Any dull ache or sense of heaviness in the scrotum that wasn't present before.
If you notice anything new or different — even if it's painless, even if it's small — see a urologist promptly. A scrotal ultrasound performed the same day can provide reassurance or confirm the diagnosis. There is no downside to getting checked early; there can be a significant downside to waiting.
Whether you’re seeking expert care for a urological condition or looking for a second opinion, we’re here to support you every step of the way. Reach out to schedule an appointment, ask questions, or learn more about personalized, minimally invasive treatment options tailored to your needs.
